BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics
BVXV Price/Volume Stats
| Current price | $1.36 | 52-week high | $11.80 |
| Prev. close | $1.31 | 52-week low | $1.25 |
| Day low | $1.32 | Volume | 23,000 |
| Day high | $1.37 | Avg. volume | 127,289 |
| 50-day MA | $1.37 | Dividend yield | N/A |
| 200-day MA | $2.73 | Market Cap | 2.54M |
BVXV Stock Price Chart Interactive Chart >
BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio
Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.
Latest BVXV News From Around the Web
Below are the latest news stories about BIONDVAX PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate BVXV as an investment opportunity.
BiondVax Reports Second Quarter Financial Results and Provides Business UpdateJERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update. Second Quarter 2023 Financial Summary R&D expenses for the three months ended J |
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesJERUSALEM, Aug. 01, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550(b) and provided it an extension until October 30, 2023, to demonstrate compliance. As previ |
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.LOS ANGELES, July 11, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel |
BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisBroad-based collaboration with Max Planck and University Medical Center Gottingen yields attractive anti-IL-17 VHH antibodies (NanoAbs); includes exclusive worldwide license for all potential indications, beginning with psoriasis.BiondVax to lead development and commercialization of NanoAbs with potential to neutralize IL-17A, IL-17F and IL-17A/F isoforms with high potency; ex vivo proof-of-concept expected this year, in vivo early next year.Psoriasis affects over 3% of U.S. population, with glo |
BVXV: Developing anti-IL-17 NanoAbBy David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT Business Update Developing Anti-IL-17 NanoAb BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) is a biopharmaceutical company that is focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. In March 2022, the company signed a |
BVXV Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | -5.00% |
| 1-year | -86.12% |
| 3-year | -95.61% |
| 5-year | -97.50% |
| YTD | -54.05% |
| 2022 | -87.40% |
| 2021 | -16.37% |
| 2020 | -69.75% |
| 2019 | 94.76% |
| 2018 | -11.01% |
Loading social stream, please wait...